Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs.
Drug-metabolizing enzyme activity is one of many factors affecting patient response to medications. The objective of this review is to highlight the potential for genetic variability in cytochrome P450 enzyme activity that can lead to interperson differences in response to drugs. Awareness and application of this knowledge will improve drug use in clinical practice and provide the physician with further appreciation that standard drug dosing may not be appropriate in all patients.
Rogers
Janyce F
JF
Clinical Pharmacology Research Center, Bassett Healthcare, Cooperstown, New York 13326-1394, USA.
Nafziger
Anne N
AN
Bertino
Joseph S
JS
D000889:Anti-Arrhythmia Agents / Q000378:metabolism; D000929:Antidepressive Agents, Tricyclic / Q000378:metabolism; D001189:Aryl Hydrocarbon Hydroxylases / Q000378:metabolism; D003061:Codeine / Q000378:metabolism; D065731:Cytochrome P-450 CYP2C19; D065729:Cytochrome P-450 CYP2C9; D019389:Cytochrome P-450 CYP2D6 / Q000378:metabolism; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D003975:Diazepam / Q000378:metabolism; D005838:Genotype; D005913:Glipizide / Q000378:metabolism; D006801:Humans; D006899:Mixed Function Oxygenases / Q000378:metabolism; D009853:Omeprazole / Q000378:metabolism; D010597:Pharmacogenetics; D010641:Phenotype; D010672:Phenytoin / Q000378:metabolism; D014859:Warfarin / Q000378:metabolism
D000889:Anti-Arrhythmia Agents; D000929:Antidepressive Agents, Tricyclic; D014859:Warfarin; D010672:Phenytoin; D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D019389:Cytochrome P-450 CYP2D6; D009853:Omeprazole; D003975:Diazepam; D003061:Codeine; D005913:Glipizide